The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold $3 billion of Amazon… it’s why Nvidia’s CEO just sold $713 million... and it’s why Zuckerberg just sold $1.3 billion in Meta stock. The financial establishment doesn’t want you to know about this… but a controversial new documentary just pulled back the curtain and exposed what’s really going on. It’s called The Final Frontier.

Including the name of the #1 company to buy.

William A. Jones, Jr. net worth and biography

William Jones, Jr. Biography and Net Worth

Insider of Biohaven

Mr. Jones has over 20 years of commercial experience in the healthcare industry and has held leadership roles of increasing responsibility at Takeda Pharmaceuticals, Inc., Bristol-Myers Squibb, Boehringer-Ingelheim, NitroMed and AstraZeneca. He has significant experience in mass market product launches, including Excedrin Migraine, Abilify, Farxiga, Pradaxa, and BiDil. BJ has successfully built and led diverse commercial teams committed to addressing unmet patient needs across various therapeutic areas, including neuroscience (migraine, schizophrenia, bipolar, depression), CV (CHF, atrial fibrillation), diabetes (type 2 - oral and injectable), respiratory, GI, and infectious disease. He holds a Bachelor of Science degree from the U.S. Air Force Academy, a Master of Science degree in Industrial Engineering from Texas A&M University and an MBA from Stanford Graduate School of Business. Prior to joining the pharmaceutical industry, BJ served in the U.S. Air Force and earned the rank of Major.

What is William A. Jones, Jr.'s net worth?: The estimated net worth of William A. Jones, Jr. is at least $1.45 million as of November 2nd, 2020. Mr. Jones, Jr. owns 31,755 shares of Biohaven stock worth more than $1,447,710 as of November 23rd. This net worth approximation does not reflect any other investments that Mr. Jones, Jr. may own. Learn More about William A. Jones, Jr.'s net worth.
How do I contact William A. Jones, Jr.?: The corporate mailing address for Mr. Jones, Jr. and other Biohaven executives is 215 CHURCH STREET, NEW HAVEN CT, 06510. Biohaven can also be reached via phone at 203-404-0410 and via email at [email protected]. Learn More on William A. Jones, Jr.'s contact information.
Has William A. Jones, Jr. been buying or selling shares of Biohaven?: William A. Jones, Jr. has not been actively trading shares of Biohaven during the last quarter. Most recently, William A. Jones, Jr. sold 30,000 shares of the business's stock in a transaction on Monday, November 2nd. The shares were sold at an average price of $76.22, for a transaction totalling $2,286,600.00. Following the completion of the sale, the insider now directly owns 31,755 shares of the company's stock, valued at $2,420,366.10. Learn More on William A. Jones, Jr.'s trading history.
Who are Biohaven's active insiders?: Biohaven's insider roster includes Irina Antonijevic (Director), Gregory Bailey (Director), Robert Berman (Insider), Matthew Buten (CFO), John Childs (Director), George Clark (CAO), Vlad Coric (CEO), Declan Doogan (Director), James Engelhart (CFO), Kimberly Gentile (SVP), Julia Gregory (Director), William Jones, Jr. (Insider), Elyse Stock (Insider), and John Tilton (Insider). Learn More on Biohaven's active insiders.
Are insiders buying or selling shares of Biohaven?: In the last twelve months, Biohaven insiders bought shares 8 times. They purchased a total of 307,186 shares worth more than $12,231,711.54. In the last twelve months, insiders at the sold shares 1 times. They sold a total of 11,000 shares worth more than $459,690.00. The most recent insider tranaction occured on October, 2nd when Director John W Childs bought 21,052 shares worth more than $999,970.00. Insiders at Biohaven own 16.0% of the company. Learn More about insider trades at Biohaven.
Information on this page was last updated on 10/2/2024.

William A. Jones, Jr. Insider Trading History at Biohaven

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/2/2020	Sell	30,000	$76.22	$2,286,600.00	31,755

William A. Jones, Jr. Buying and Selling Activity at Biohaven

Biohaven Company Overview

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

Today's Range

Now: $45.59

$45.08

$47.15

50 Day Range

MA: $48.95

$38.08

$53.73

2 Week Range

Now: $45.59

$26.80

$62.21

Volume

691,029 shs

Average Volume

1,129,495 shs

Market Capitalization

$4.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.31

Financial Prophecy

From Porter & Company | Ad